7P An optimized Breast Cancer Index node-positive (BCIN+) prognostic model for late distant recurrence in patients with hormone receptor-positive (HR+) node-positive breast cancer

Abstract

BCI is a gene expression-based assay that reports a prognostic BCI score that significantly predicts risk of overall (10y), early (0-5y), and late (≥5y) distant recurrence (DR) in HR+, node-negative (N0) and node-positive (N1) breast cancer. The BCIN+ prognostic model was trained in the Trans-ATAC cohort, which evaluated primary adjuvant anastrozole versus tamoxifen. The current study optimized the BCIN+ prognostic model for late DR in N+ patients from the arm treated with 7.5 years of endocrine therapy in the translational cohort of the IDEAL trial.